The drug ACNATAC contains a combination of these active pharmaceutical ingredients (APIs):
Clindamycin is a lincosamide antibiotic with a primarily bacteriostatic action against Gram-positive aerobes and a wide range of anaerobic bacteria. Lincosamides such as clindamycin bind to the 50S subunit of the bacterial ribosome and inhibit the early stages of protein synthesis.
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
This brand name is authorized in the following countries: Austria Cyprus Finland Poland Romania
This drug has been assigned below unique identifiers within the countries it is being marketed: